Geode Capital Management
CAI

Geode Capital Management’s Caris Life Sciences CAI Stock Holding History

Geode Capital Management’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.6M Buy
1,044,657
+266,125
+34% +$4.76M ﹤0.01% 2197
2026
Q1 		$13.9M Buy
778,532
+405,553
+109% +$8.86M ﹤0.01% 2197
2025
Q4 		$10.1M Sell
372,979
-25,349
-6% -$714K ﹤0.01% 2412
2025
Q3 		$12M Buy
398,328
+163,094
+69% +$5.2M ﹤0.01% 2311
2025
Q2 		$6.29M Buy
+235,234
New +$6.34M ﹤0.01% 2611

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management's CAI Position: Q2 2026 in Review

Geode Capital Management increased its Caris Life Sciences (CAI) stake by 34% in Q2 2026, buying an estimated $4.76M and bringing the position to 1,044,657 shares worth $18.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2197.

Geode Capital Management first reported a position in CAI in Q2 2025 and has held it in 5 quarters since. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Geode Capital Management held 1,044,657 shares of Caris Life Sciences worth $18.6M as of Q2 2026.
  • Geode Capital Management bought 266,125 Caris Life Sciences shares in Q2 2026, an estimated $4.76M.
  • Caris Life Sciences made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2197 holding.
  • Geode Capital Management first reported a position in Caris Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.